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INCIDENCE AND COST OF ADVERSE EVENTS (AES) IN PATIENTS 
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OBJECTIVES: The incidence of AEs and the costs associated with the management 
of those AEs have not been widely studied in patients with RCC receiving bevacizu-
mab, sorafenib, or sunitinib. This study evaluates these outcomes using a large claims 
database. METHODS: Patients with ≥ 2 RCC claims (ICD-9 189.0, 198.0) were 
identiﬁed in a large US commercial insurance claims database from 1/02 through 
12/08. Patients were observed and analyzed during the time of their ﬁrst AI treatment 
with bevacizumab, sorafenib, or sunitinib. AEs were deﬁned as diagnoses that were 
treatment-emergent (i.e., diagnoses not present in the 6 months prior to initiation of 
AI treatment). The incidence rate (IR) and mean cost per visit for each AE were cal-
culated in the outpatient, inpatient and ER settings. Cost data represented actual 
payments made by insurers. RESULTS: The inclusion criteria identiﬁed 269 bevaci-
zumab, 375 sorafenib, and 672 sunitinib patients. The three most frequent AEs 
experienced by patients in each treatment group were identiﬁed based on the overall 
IR. The setting-speciﬁc IRs and costs per visit for these AEs are: bevacizumab: outpa-
tient = 20.3/$1,522, 16.1/$652, 11.6/$91; inpatient = 3.9/$8,222, 1.5/$15,848, 
1.4/$4,808; ER = 3.8/$643, 0.7/$24, 0.8/$176 for anemia, lung diseases, and hyperten-
sion, respectively; sorafenib: outpatient = 24.1/$525, 19.2/$226, 11.0/$288; inpatient 
= 1.1/$8,205, 3.7/$6,104, 1.6/$18,001; ER = 0/$0, 2.3/$218, 10.3/$294 for lung 
diseases, hypertension, and abdominal pain, respectively; sunitinib: outpatient = 
31.1/$176, 26.5/$990, 23.3/$1,183; inpatient = 3.7/$13,183, 0.4/$30,843, 
2.7/$13,727; ER = 7.6/$409, 0/$0, 2.0/$606 for hypertension, lung diseases, and 
anemia, respectively. For outpatient treatment, there was a trend for IRs for each of 
the AEs to be the highest for sunitinib. CONCLUSIONS: Bevacizumab, sorafenib, and 
sunitinib were associated with frequent AEs, in particular abdominal pain, anemia, 
hypertension, and lung diseases. Management of these and other AEs resulted in 
signiﬁcant medical treatment costs. These results can be used in economic evaluations 
of various currently available targeted therapies for RCC.
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WITH STAGE 3 CHRONIC KIDNEY DISEASE WITH ANEMIA
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OBJECTIVES: Chronic Kidney Disease (CKD) is a signiﬁcant health care problem in 
the United States; iron deﬁciency anemia can greatly impact resource utilization. We 
compared patient and health characteristics and health care utilization of members 
with stage 3 CKD with anemia versus without anemia in a regional integrated health 
care system. METHODS: Patients 18 and older were identiﬁed with a calculated GFR 
between 30 and 59 ml/min/1.73m3 (stage 3) using the MDRD equation or ICD-9 
diagnosis code of 585.3 between July 1, 2004 and June 30, 2007. Patients were 
required to be continuously enrolled for 6 months pre- and 24 months post-index 
dates. Anemia patients were identiﬁed with ICD-9 codes (280.0–280.9, 285.21, 
285.29, or 285.9) or hemoglobin values (<13, male; <12, female). Dialysis patients 
were excluded. Descriptive and inferential statistics were utilized. RESULTS: 2,739 
patients met inclusion criteria; 24% (n = 648) had anemia. 8.4% (n = 231) of patients 
were identiﬁed by ICD-9, while 17% (n = 113) of anemia patients had the above 
ICD-9 codes. Mean age was 73.3 and 71.5 years (p < 0.001) for with anemia and 
without anemia groups, respectively. 58% and 27% of anemia patients had comorbid 
hypertension and diabetes, respectively, versus 50% and 19% in the without anemia 
group. Per patient visit to nephrology, inpatient, and ED were as follows: 0.52, 4.33, 
and 0.53 for anemia, 0.19, 1.74, and 0.28 for without anemia (p < 0.001). Average 
health care costs during the post-index period was 59% higher (p < 0.001) for anemia 
patients versus patients without anemia. 8% of anemia patients progressed to stage 4 
versus 4.5% for without anemia patients. 20.1% (n = 130) of anemia patients were 
treated with either an erythropoietin stimulating agent (14.5%) or intravenous iron 
therapy (5.6%); 3.9% (n = 25) were treated with both. CONCLUSIONS: CKD 
remains under-diagnosed and patients with anemia utilize more resources compared 
to CKD patients without anemia; however, anemia remains under-treated.
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EVALUATION OF SIMULTANEOUS LIVER KIDNEY TRANSPLANTATION 
VERSUS LIVER TRANSPLANTATION ALONE FOR END-STAGE LIVER 
DISEASE PATIENTS WITH IMPAIRED RENAL FUNCTION – A 
COMPARATIVE EFFECTIVENESS ANALYSIS
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OBJECTIVES: Simultaneous liver kidney (SLK) transplant improves the survival of 
liver transplant candidates with renal insufﬁciency. The indication for SLK transplant 
remains controversial due to potential renal recovery after liver transplant alone 
(LTA). This study aims to (1) investigate the difference in survival between SLK and 
LTA recipients and (2) estimate the additional number of kidney grafts utilized for 
SLK transplant. METHODS: The Markov decision model was constructed to simulate 
a hypothetical cohort of liver transplant candidates with impaired renal function to 
receive either (1) LTA or (2) SLK transplant strategy. Transplant candidates in each 
strategy were categorized into 4 groups, based on the Model for End-Stage Liver 
Disease (MELD) score. LTA recipients without recovering renal function within three 
months post-transplant were subsequently placed on the kidney transplant waiting 
list. Liver re-transplant and kidney re-transplant were considered in the model for 
acute and chronic graft failure post-transplant. The simulation period was 10 years. 
Microsimulations were conducted to estimate survival by averaging outcomes of 
10,000 trials for each transplant strategy. The values and ranges of parameters in the 
model were obtained from the United Network for Organ Sharing (UNOS) and the 
Scientiﬁc Registry of Transplant Recipients (SRTR) data and published literature. 
RESULTS: The model demonstrates a mean survival of 67.6 months and 61.6 months 
for SLK and LTA recipients, respectively. Of the 10,000 trials, 4,181 isolated kidney 
transplants were performed when using the LTA strategy. The SLK transplant recipient 
survival was 6.1 months longer than LTA recipient survival. However, this SLK 
survival beneﬁt occurred at the expense of an additional 69.3 kidney grafts per 100 
SLK transplants performed when compared with LTA. CONCLUSIONS: An addi-
tional 69.3 kidney grafts per 100 SLK transplants are required to achieve a 6.1 month 
improvement in survival for SLK transplant recipients.
PUK4
EFFECT OF ATYPICAL ANTIPSYCHOTICS ON URINARY 
INCONTINENCE IN US NURSING HOME RESIDENTS USING 
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OBJECTIVES: Psychotropics have been widely used in nursing homes. Case reports 
and review articles have implicated that atypical antipsychotics may enhance the risk 
of urinary incontinence (UI); a condition prevalent in more than half the nursing home 
residents (NHR). With antipsychotics being the most extensively prescribed psycho-
tropic medication in nursing homes, the objective of this study was to investigate the 
effect of atypical antipsychotics on UI in NHR using psychotropic medications. 
METHODS: The 2004 National Nursing Home Survey (NNHS) was used as the data 
source. Logistic regression was performed to determine relationship between UI and 
use of atypical antipsychotics, in presence of other covariates. Sample data was 
weighted and data analysis was performed using SAS 9.1. RESULTS: From the origi-
nal 13507 NNHS residents, 64.57% (n = 8722) used psychotropic medications; of 
which 27.22% (n = 2366) used atypical antipsychotics and 57.58% (n = 5005) were 
incontinent. Among those using psychotropics, incontinent residents were older than 
their continent counterparts (81.48 ± 12.01years versus 77.45 ± 13.67years, p < 
.0001). Regression analysis shows that residents on atypical antipsychotics had 81.5% 
increased risk of being incontinent (OR = 1.815, p < 0.0001). Concomitant use of 
other medications which may increase incontinence risk was not signiﬁcantly associ-
ated with UI (p = 0.1016). Presence of comorbidities enhanced UI risk by 58.9% (OR 
= 1.589, p < .0001). Residents who were ADL dependent (OR = 1.224, p < .0001) or 
used bedrails (OR = 1.264, p < 0.0157), chairs (OR = 1.708, p < 0.0118) or truncal 
restraints (OR = 1.501, p < 0.0238) also had higher risks of being incontinent. Advanc-
ing age (OR = 1.022, p < 0.0001) and female gender (OR = 1.160, p = 0.0353) were 
also found to be other risk factors. CONCLUSIONS: The study results indicate that 
use of atypical antipsychotics leads to increased UI risk. Since coping with UI continues 
to be a challenge in elderly population, newer antipsychotic medications should be 
developed to ensure safer treatments. In addition, closely monitoring the resident’s 
functional status and use of physical restraints would also help minimize incontinence 
episodes.
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DOES RACIAL VARIATION IN RISK FACTORS HAVE A ROLE TO PLAY 
IN THE INCIDENCE OF CHRONIC KIDNEY DISEASE IN THE US 
POPULATION
Shah J, Nair R
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OBJECTIVES: To compare racial variations in risk factors associated with incidence 
of Chronic Kidney Disease (CKD) in a sample population (age >11 years) and look for 
possible early indicators. METHODS: A retrospective study was conducted using the 
NHANES 2003–2004 database comprising of a nationally representative sample con-
taining nutritional and health records. Patients were screened on the basis of their 
Glomerular ﬁltration rates and a sample with an estimated Glomerular Filtration Rate 
(eGFR) <60ml/min/1.73m2 was included in the study. The eGFR was calculated using 
the 6-variable MDRD equation. Demographics and laboratory records such as Blood 
Pressure, cholesterol, glucose, albumin, serum creatinine and Vitamin D levels were 
recorded. RESULTS: An eGFR <60 ml/min/1.73m2 was observed in 413 (5.6%) of 
7344 NHANES participants; of which 71.16% were Non-Hispanic Whites, 10.89% 
were African-Americans and 11.13% were Mexican Americans. Lower prevalence 
amongst African-Americans and Mexican-Americans was not seen to be uniform in 
higher stages of CKD. Vitamin D deﬁciency was noticeable in African-Americans and 
Mexican Americans compared to Non-Hispanic Whites at 15.28ng/ml (95% CI 12.82–
17.74), 17.17ng/ml (95% CI 14.87–19.47) and 24.46ng/ml (95% CI 23.46–25.47) 
respectively. Serum Creatinine levels were recorded as 1.717mg/dl (95% 
CI 1.287–2.147), 2.351mg/dl (95% CI 1.565–3.136) and 1.355mg/dl (95% CI 
1.303–1.406) for Mexican-Americans, African-Americans and Non-Hispanic Whites 
respectively. CONCLUSIONS: Higher prevalence of African-Americans and Mexican-
